Enapotamab Biosimilar – Anti-AXL mAb – Research Grade

Introduction to Enapotamab Biosimilar – Anti-AXL mAb

Enapotamab Biosimilar – Anti-AXL mAb, also known as ABT-414, is a monoclonal antibody (mAb) that specifically targets the AXL receptor tyrosine kinase. This biosimilar is a research grade version of the original ABT-414 antibody and is used for scientific research purposes.

Structure of Enapotamab Biosimilar – Anti-AXL mAb

Enapotamab Biosimilar – Anti-AXL mAb is a fully human IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the AXL receptor, while the constant region is responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Enapotamab Biosimilar – Anti-AXL mAb

The AXL receptor is a member of the TAM (Tyro3, AXL, and MERTK) family of receptor tyrosine kinases. It is overexpressed in a variety of cancers, including breast, lung, and brain cancers, and has been shown to play a role in tumor growth, invasion, and metastasis. Enapotamab Biosimilar – Anti-AXL mAb specifically binds to the AXL receptor and blocks its activity, inhibiting tumor growth and metastasis.

In addition to blocking AXL signaling, Enapotamab Biosimilar – Anti-AXL mAb also has effector functions that can contribute to its anti-tumor activity. It can induce ADCC, where immune cells such as natural killer (NK) cells recognize and kill AXL-expressing cancer cells. It can also activate CDC, where the antibody binds to the cancer cell and triggers the complement cascade, leading to the lysis of the cancer cell.

Application of Enapotamab Biosimilar – Anti-AXL mAb

Enapotamab Biosimilar – Anti-AXL mAb has shown promise in preclinical studies as a potential therapeutic for various cancers. It has been shown to inhibit tumor growth and metastasis in breast, lung, and brain cancer models. In addition, it has been shown to enhance the efficacy of other cancer therapies, such as chemotherapy and radiation therapy, in preclinical studies.

Currently, Enapotamab Biosimilar – Anti-AXL mAb is being evaluated in clinical trials for the treatment of glioblastoma, a type of brain cancer. It is also being studied in combination with other cancer therapies for the treatment of various solid tumors. As a research grade antibody, it is also widely used in scientific research to study the role of AXL signaling in cancer and to develop new therapies targeting AXL.

Conclusion

Enapotamab Biosimilar – Anti-AXL mAb is a promising monoclonal antibody that specifically targets the AXL receptor, a therapeutic target in various cancers. Its structure, activity, and application make it a valuable tool for studying AXL signaling and developing new cancer therapies. As research on this biosimilar continues, it has the potential to improve the treatment options for cancer patients and contribute to the advancement of cancer research.